

## Antifibrotic Activity of LCC, a Cerebroside of *Lycium chinense* Fruit, in Bile Duct-Ligated Rats

Sun Yeou Kim<sup>2</sup>, Hong Pyo Kim<sup>1,4</sup>, Hyekyung Yang<sup>1</sup>, Mina Lee<sup>1</sup>, Hyo Jeong Ryu<sup>1</sup>, Young Pyo Jang<sup>3</sup>, Sang Hyun Sung<sup>1</sup> and Young Choong Kim<sup>1,\*</sup>

<sup>1</sup>College of Pharmacy and Research Institute of Pharmaceutical Science, Seoul National University, Seoul 151-742, Korea

<sup>2</sup>Graduate School of East-West Medical Science, Kyung Hee University, Kyungki-Do 449-701, Korea

<sup>3</sup>College of Pharmacy, Kyung Hee University, Seoul 130-701, Korea

<sup>4</sup>Present address: Pulmonary and Critical Care Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02117

**Abstract** – We previously reported that a novel cerebroside, LCC, isolated from the fruits of *Lycium chinense* (Solanaceae), significantly exerted hepatoprotective activity against both the carbon tetrachloride-induced and galactosamine-induced toxicities in primary cultures of rat hepatocytes. In the present study, we further attempted to determine the effect of LCC on hepatic fibrosis in animal model. Hepatic fibrosis was induced in rats by bile duct ligation/scission (BDL) for a period of 5 weeks. Treatment of BDL rats with LCC significantly reduced collagen deposition and the activities of serum alkaline phosphatase and  $\gamma$ -glutamyl transpeptidase. In addition, the LCC treatment of BDL rats significantly preserved the decreased hepatic glutathione as well as the activities of glutathione reductase and catalase in BDL rats. From the results, it can be speculated that LCC might exert antifibrotic activity in rats with BDL, in part, through the preservation of antioxidant enzymes and hepatic glutathione.

**Keywords** – LCC, Bile duct ligation/scission, *Lycium chinense*, Hepatic fibrosis, Antifibrotic activity, Antioxidative activity

### Introduction

Hepatic fibrosis is one of the most frequent lesions in chronic liver diseases and has been characterized by an increased accumulation of extracellular matrix (ECM) protein including collagen (Hui and Friedman, 2003; Friedman, 2004). It is well recognized that hepatic fibrosis has been associated with oxidative stress. That is, lipid peroxidation has been observed in hepatic fibrosis caused by iron overload (Gualdi *et al.*, 1994), ethanol (Kamimura *et al.*, 1992; Niemela *et al.*, 1995), carbon tetrachloride (CCl<sub>4</sub>) (Tsukamoto *et al.*, 1990) and bile duct ligation/scission (Fox *et al.*, 1997; Pastor *et al.*, 1997). Therefore, enhancement of antioxidative defense mechanism has been proposed as a mean to protect against some clinical manifestations of fibrosis (Hernandez-Munoz *et al.*, 1997; Muriel and Moreno, 2004; Loguericio *et al.*, 2007).

In our previous study, we reported that a novel


cerebroside isolated from the fruits of *Lycium chinense* (Solanaceae), 1-*O*-( $\beta$ -D-glucopyranosyl)-(2*S*,3*R*,4*E*,8*Z*)-2-*N*-palmitoyloctadecasphinga-4,8-diene (LCC) (Fig. 1), significantly exerted hepatoprotective activity against both the CCl<sub>4</sub>-induced and galactosamine-induced toxicities in primary cultures of rat hepatocytes through maintaining the hepatic glutathione (GSH) redox system (Kim *et al.*, 1997, 1999 and 2000). As a continuation of the study, we attempted to determine the antifibrotic activity of LCC in an animal model.

### Experimental

**Animal model for hepatic fibrosis** – Female Wistar rats weighing around 200 g were obtained from the Laboratory Animal Center, Seoul National University. They were kept on standard rat chow with free access to tap water, in temperature- and humidity-controlled animal quarters under a 12-h light-dark cycle. All experiments were conducted according to the guidelines of the Committee on Care and Use of Laboratory Animals of

\*Author for correspondence

Tel: +82-2-880-7842; E-mail: youngkim@snu.ac.kr



**Fig. 1.** Chemical structure of a cerebroside, LCC, isolated from *L. chinensis* fruits.

Seoul National University.

Secondary biliary fibrosis was induced by BDL as described previously (Kountouras *et al.*, 1984; Kim *et al.*, 1993). The sham-operated rats and BDL rats served as control groups. LCC was daily given at 10 a.m. *per os* at a dose of 6.25 and 12.5 mg/kg body weight (in 5% Tween 80) to the BDL rats throughout the experimental period. After 5 weeks of biliary obstruction, sham-operated rats, BDL rats and BDL rats treated with LCC were sacrificed under urethane and blood was collected by heart puncture. A lobe of the liver was rapidly removed for the determination of the activity of antioxidant enzymes and the contents of GSH and 4-hydroxyproline. Liver sections fixed by 10% formalin and frozen were used to determine hepatic collagen content. Serum was obtained for the determination of alanine aminotransferase (ALT), alkaline phosphatase (ALP), and  $\gamma$ -glutamyl transpeptidase (GGT).

**Determination of hepatic collagen content** – The collagen content in liver section was determined by the method of Lopez de Leon and Rojkind (1985), as validated by Jimenez *et al.* (1985).

**Determination of 4-hydroxyproline content** – The frozen middle lobe of liver (30 - 50 mg) was lyophilized overnight. This lyophilized tissue was ground into powder and subsequently extracted five times with 2 ml of diisopropylether to remove vitamin A. It was then hydrolyzed with 6 N HCl for 20 h at 100 °C. The hydrolysate was filtered through a 0.22- $\mu$ m Millipore filter. The content of 4-hydroxyproline in the liver hydrolysate was determined as described by the method of Jamall *et al.* (1981).

**Biochemical analysis of blood** – The activity of ALT was measured according to the method of Reitman and Frankel (1957) using an assay kit obtained locally (Youngdong Pharmaceuticals, Seoul, Korea). ALP activity was measured according to the method of Tietz *et al.* (1983), and GGT activity was determined by the method of Glossman and Nevile (1972) using  $\gamma$ -glutamyl-*p*-nitroaniline as a substrate.

**Determination of GSH content and antioxidant enzyme activity** – The content of GSH was determined

by the method of Hissin and Hilf (1976). GSH-S-transferase (GST), GSH peroxidase (GPx) and GSH disulfide reductase (GR) activities were determined as described by Carlberg and Mannervik (1975); Flohe and Gunzler (1984); Habig *et al.* (1974), respectively. Catalase activity was measured by the method of Beers and Sizer (1952). Protein concentration was determined by the Lowry method (Lowry *et al.*, 1951).

**Statistical analysis** – All data are expressed as the mean  $\pm$  S.D. Group means are evaluated for statistically significant differences using analysis of variance (one way ANOVA). Values of  $p < 0.05$  were considered statistically significant differences.

## Results and Discussion

The BDL rat model has been recognized as a representative experimental model for studying cholestasis and cirrhosis (Kountouras *et al.*, 1984; Mullen and McCullough, 1989; Kim *et al.*, 1993). Dueland *et al.* (1991) reported that after the BDL for 4 to 5 weeks, liver cirrhosis in rats occurred by the newly formed duct-like structure associated with collagen deposition, mainly type I and III, in liver tissue. It was also reported that cirrhotic liver contained more than 15 mg of collagen per gram tissue than normal tissue and the content of other ECM material was also increased (Rojkind *et al.* 1983). In this experiment, we found similar morphological changes in BDL rat after 5 weeks of BDL. In addition, BDL results in the increase in spleen weight, an indicator of portal hypertension, and liver weight because of pathological defense mechanism and collagen deposition (Kountouras *et al.*, 1984). We also found similar histological changes in BDL rats after 5 weeks of BDL (Table 1). Weights of liver and spleen were significantly increased in BDL rats compared to the sham-operated control rats ( $p < 0.001$ ). However, the treatment of BDL rats with LCC at a dose of 6.25 and 12.5 mg/kg body weight/day, respectively, significantly lowered the increased weights of liver and spleen ( $p < 0.05$ ) in BDL rats. There were no significant differences in body weight between BDL rats and BDL rats treated with LCC.

Excessive production and deposition of ECM such as collagen are important characteristics of hepatic fibrosis (Hui and Friedman, 2003). Thus, we determined collagen deposition by the selective dye-binding method of collagen quantitative assay (Lopez de Leon and Rojkind, 1985). After 5 weeks of BDL, hepatic collagen content in BDL rats increased to 1.2-fold compared to that in sham-operated controls (Table 2). The treatment of BDL rats

**Table 1.** Weights of body, liver and spleen in BDL rats.

| Group          | n  | Body weight (g) |          | Liver weight (g) | Spleen weight (g) |
|----------------|----|-----------------|----------|------------------|-------------------|
|                |    | 0 wks           | 5 wks    |                  |                   |
| Sham-operated  | 12 | 220 ± 19        | 240 ± 14 | 8.9 ± 1.1        | 0.65 ± 0.07       |
| BDL            | 10 | 223 ± 12        | 259 ± 26 | 17.5 ± 3.3       | 1.52 ± 0.27       |
| LCC 6.25 + BDL | 13 | 223 ± 17        | 242 ± 22 | 13.4 ± 2.1*      | 1.26 ± 0.24*      |
| LCC 12.5 + BDL | 14 | 212 ± 18        | 239 ± 21 | 12.5 ± 2.8*      | 0.95 ± 0.17**     |

LCC was given at a dose of 6.25 or 12.5 mg/kg body weight/day for 5 weeks. Sham-operated rats were given vehicle (5% Tween 80). Data are expressed as the mean ± S.D.

\*, \*\* Significantly different from BDL control at  $p < 0.05$  and  $0.01$ , respectively.

**Table 2.** Effects of LCC on the contents of hydroxyproline and collagen in liver tissue of BDL rats.

| Groups         | Hydroxyproline (µg/g liver) | Collagen (µg/mg total protein) |
|----------------|-----------------------------|--------------------------------|
| Sham-operated  | 54.5 ± 8.7                  | 102.81 ± 5.19                  |
| BDL            | 108.9 ± 13.6                | 119.08 ± 6.44                  |
| LCC 6.25 + BDL | 115.1 ± 19.7                | 111.45 ± 5.62*                 |
| LCC 12.5 + BDL | 88.7 ± 11.8*                | 105.84 ± 8.11*                 |

LCC was given at a dose of 6.25 or 12.5 mg/kg body weight/day for 5 weeks. Sham-operated rats were given vehicle (5% Tween 80). Collagen content in liver sections was measured by the selective binding of Sirius red and Fast Green to collagen and non-collagen protein, respectively. Hydroxyproline content in liver hydrolysates was determined spectrophotometrically as described in "Experimentals". Data are expressed as the means ± SD. \* Significantly different from BDL rats at  $p < 0.05$ .

with LCC at a dose of 12.5 mg/kg body weight/day significantly reduced the increased collagen content induced by BDL (Table 2). The result was consistent with the reduction of 4-hydroxyproline content in liver tissues of BDL rats treated with LCC. The 4-hydroxyproline content in liver tissues increased 2-fold after 5 weeks of BDL. However, the treatment of BDL rats with LCC at a dose of 12.5 mg/kg body weight/day decreased the 4-hydroxyproline content to 18.5% of that in BDL rats ( $p < 0.05$ ). These results suggested that LCC inhibit the collagen synthesis at the translational level because it significantly reduced the hydroxyproline content. It was also speculated that antifibrotic effect of LCC might be involved in the inhibition of prolyl-4-hydroxylase, a key enzyme of collagen fibril production that catalyzes the hydroxylation of peptide-bound proline residues to 4-hydroxyproline, which needs to be further clarified (Bickel *et al.*, 1998; Aoyagi *et al.*, 2002).

Serum GGT is an enzyme embedded in the canalicular domain of the liver. The liberation of this enzyme to serum indicates damage to the plasma membrane of hepatocyte by lipid peroxidation and thus injury to the liver as mentioned in elsewhere (Bulle *et al.*, 1990;

**Table 3.** Effects of LCC on activities of serum and cholestatic enzymes in BDL rats.

| Group          | ALT (U/L)   | ALP (U/L)    | GGT (U/L)     |
|----------------|-------------|--------------|---------------|
| Sham-operated  | 18.1 ± 6.81 | 102.3 ± 29.0 | 0.00 ± 0.01   |
| BDL            | 72.4 ± 7.52 | 184.6 ± 30.8 | 17.64 ± 4.57  |
| LCC 6.25 + BDL | 69.3 ± 6.07 | 141.2 ± 23.8 | 8.65 ± 2.19*  |
| LCC 12.5 + BDL | 65.7 ± 6.43 | 90.3 ± 11.5* | 6.82 ± 1.24** |

LCC was given at a dose of 6.25 or 12.5 mg/kg body weight/day for 5 weeks. Sham-operated rats were given vehicle (5% Tween 80). Data are expressed as means ± SD. \*, \*\* Significantly different from BDL control at  $p < 0.05$  and  $p < 0.01$ , respectively.

Muriel, 1998). As shown in Table 3, the level of serum GGT increased from  $0.0 \pm 0.01$  in sham-operated to  $17.64 \pm 5.87$  in BDL rats, indicating that the level of serum total bilirubin was increased after BDL. However, the treatment of BDL rats with LCC at a dose of 6.5 and 12.5 mg/kg body weight/day, respectively, significantly reduced the elevated level of serum GGT to  $6.82 \pm 1.24$  ( $p < 0.05$ ) and  $8.65 \pm 2.19$  ( $p < 0.01$ ), respectively. In BDL rats treated with LCC at a dose of 12.5 mg/kg body weight/day, serum ALP activity was significantly reduced to 51% of those of BDL rats ( $p < 0.05$ ) (Table 3). These results indicated that the effective dose of LCC in treatment of liver cholestasis in BDL rats is 12.5 mg/kg body weight/day. There was no significant difference between BDL rats and BDL rats treated with LCC in serum ALT activities.

In our previous study, we found that LCC could protect primary cultured rat hepatocytes from oxidative stress induced by  $\text{CCl}_4$  by maintaining hepatic GSH level (Kim *et al.*, 1999). It is well known that obstruction of bile flow by BDL causes the accumulation and retention of hydrophobic bile salts in the liver, which leads to increase in oxygen radical production and remarkably decline in antioxidant defenses such as GSH (Krahebuhl *et al.*, 1995; Benedetti *et al.*, 1997; Roeb *et al.*, 2003). The present study clearly showed that BDL for 5 weeks in rats profoundly reduced in the activity of antioxidant enzymes

**Table 4.** Effects of LCC on GSH content and antioxidant enzyme activities in liver tissue of BDL rats.

| Group          | GSH           | GST         | GPx           | GR             | Catalase      |
|----------------|---------------|-------------|---------------|----------------|---------------|
| Sham-operated  | 24.78 ± 3.97  | 65.8 ± 3.60 | 0.829 ± 0.145 | 14.652 ± 1.682 | 311.6 ± 69.1  |
| BDL            | 12.22 ± 1.94  | 70.6 ± 20.6 | 0.486 ± 0.095 | 1.815 ± 0.376  | 84.2 ± 12.3   |
| LCC 6.25 + BDL | 14.99 ± 1.41  | 67.0 ± 25.4 | 0.430 ± 0.096 | 4.286 ± 0.546* | 174.9 ± 24.3* |
| LCC 12.5 + BDL | 17.66 ± 3.19* | 88.8 ± 16.2 | 0.458 ± 0.098 | 5.403 ± 0.987* | 210.7 ± 49.9* |

LCC was given at a dose of 6.25 or 12.5 mg/kg body weight/day for 5 weeks. Sham-operated rats were given vehicle (5% Tween 80). GSH: nmol/mg protein/min, GST: nmol/mg protein/min, GPx:  $\mu$ mol/mg protein/min, GR: nmol/mg protein/min, catalase:  $\mu$ mol/mg protein/min. Data are expressed as means  $\pm$  SD.

\* Significantly different from BDL control at  $p < 0.05$ .

and the reduced GSH content. As shown in Table 4, the total GSH content in liver tissue of BDL rats was decreased to the half of that in the sham operated control rats. However, the reduced GSH content in BDL rats was significantly increased by the treatment of LCC at a dose of 12.5 mg/kg body weight/day. In addition, the decreased activity of some antioxidant enzymes such as GR and catalase in BDL rats increased 2-fold by the LCC treatment. No significant differences in the activities of GPx and GST were observed by the treatment of LCC in BDL rats. The GSH depletion by BDL was significantly protected by the treatment of LCC although the decreased activities of GPx and GST were not restored ( $p < 0.05$ ), suggesting that LCC might be involved in GSH biosynthesis. This statement should be clarified with further study.

In conclusion, these findings indicate that LCC might exert antifibrotic activity in BDL rats, preserving antioxidant enzymes and hepatic GSH, in part. Based on our results, we could suggest that LCC might be of significant therapeutic potential in the prevention of hepatic fibrosis, although the antifibrotic effects of LCC in *in vitro* should be further investigated using hepatic stellate cells which are responsible for liver fibrosis.

### Acknowledgements

This study was supported by a grant (10524) from Seoul R&BD program, the Republic of Korea.

### References

- Aoyagi, M., Sakaida, I., Suzuki, C., Segawa, M., Fukumoto, Y., and Okita, K., Prolyl 4-hydroxylase inhibitor is more effective for the inhibition of proliferation than for inhibition of collagen synthesis of rat hepatic stellate cells. *Hepatol. Res.* **23**, 1-6 (2002).
- Beers, R.F. and Sizer, I.W., A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. *J. Biol. Chem.* **195**, 133-140 (1952).
- Benedetti, A., Alvaro, D., Bassotti, C., Gigliozzi, A., Ferretti, G., La Rosa, T., Di Sario, A., Baiocchi, L., and Jezequel, A.M., Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver. *Hepatology* **26**, 9-21 (1997).
- Bickel, M., Baringhaus, K.H., Gerl, M., Günzler, V., Kanta, J., Schmidts, L., Stapf, M., Tschank, G., Weidmann, K., and Wemer, U., Selective inhibition of hepatic collagen accumulation in experimental liver fibrosis in rats by a new prolyl 4-hydroxylase inhibitor. *Hepatology* **28**, 404-411 (1998).
- Bulle, F., Mavier, P., Zafrani, E.S., Preaux, A.M., Lescs, M.C., Siegrist, S., Dhumeaux, D., and Guellaën, G., Mechanism of  $\gamma$ -glutamyl transpeptidase release in serum during intrahepatic and extrahepatic cholestasis in the rat: A histochemical, biochemical and molecular approach. *Hepatology* **11**, 545-550 (1990).
- Carlberg, I. and Mannervik, B., Purification and characterization of the flavoenzyme glutathione reductase from rat liver. *J. Biol. Chem.* **250**, 5475-5480 (1975).
- Dueland, S., Reichen, J., Everson, G.T., and Davis, R.A., Regulation of cholesterol and bile acid homeostasis in bile-obstructed rats. *Biochem. J.* **280**, 373-377 (1991).
- Flohe, L. and Gunzler, W.A., Assays of glutathione peroxidase. *Methods Enzymol.* **105**, 114-121 (1984).
- Fox, E.S., Kim, J.C., and Tracy, T.F., NF-kappaB activation and modulation in hepatic macrophages during cholestatic injury. *J. Surg. Res.* **72**, 129-134 (1997).
- Friedman, S.L., Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. *Nat. Clin. Pract. Gastroenterol. Hepatol.* **1**, 98-105 (2004).
- Glossmann, H. and Neville, D.M., Glutamyl transferase in kidney brush border membranes. *FEBS Lett.* **19**, 340-344 (1972).
- Gualdi, R., Casalgrandi, G., Montosi, G., Ventura, E., and Pietrangelo, A., Excess iron into hepatocytes is required for activation of collagen type I gene during experimental siderosis. *Gastroenterology* **107**, 1118-1124 (1994).
- Habig, W.H., Pabst, M.J., and Jakoby, W.B., Glutathione S-transferases. *J. Biol. Chem.* **249**, 7130-7135 (1974).
- Hernandez-Munoz, R., Diaz-Munoz, M., Lopez, V., Lopez-Barrera, F., Yanez, L., Vidrio, S., Aranda-Fraustro, A., and Chagoya de Sanchez, V., Balance between oxidative damage and proliferative potential in an experimental rat model of CCl<sub>4</sub>-induced cirrhosis: Protective role of adenosine administration. *Hepatology* **26**, 1100-1110 (1997).
- Hissin, P.J. and Hilf, R., A fluorometric method of determination of oxidized and reduced glutathione in tissues. *Anal. Biochem.* **74**, 214-226 (1976).
- Hui, A.Y. and Friedman, S.L., Molecular basis of hepatic fibrosis. *Expert Rev. Mol. Med.* **5**, 1-23 (2003).
- Jamall, I.S., Finelli, V.N., and Que Hee, S.S., A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. *Anal. Biochem.* **112**, 70-75 (1981).
- Jimenez, W., Pares, A., Caballeria, J., Heredia, D., Bruguera, M., Torres, M., Rojkind, M., and Rodes, J., Measurement of fibrosis in needle

- liver biopsies: evaluation of a colorimetric method. *Hepatology* **5**, 815-818 (1985).
- Kamimura, S., Gaal, K., Britton, R.S., Bacon, B.R., Triadafilopoulos, G., and Tsukamoto, H., Increased 4-hydroxynonenal levels in experimental alcoholic liver disease: association of lipid peroxidation with liver fibrogenesis. *Hepatology* **16**, 448-453 (1992).
- Kim, K.Y., Schuppan, D., and Kim, J.B., The establishment of experimental liver fibrosis model in rats by two different method of biliary obstruction. *Kor. J. Lab. Ani. Sci.* **9**, 39-48 (1993).
- Kim, S.Y., Choi, Y., Huh, H., Kim, J., Kim, Y.C., and Lee, H.S., New antihepatotoxic cerebroside from *Lycium chinense* fruits. *J. Nat. Prod.* **60**, 274-276 (1997).
- Kim, S.Y., Lee, E.J., Kim, H.P., Kim, Y.C., Moon, A., and Kim, Y.C., A novel cerebroside from *Lycium Fructus* preserves the hepatic glutathione redox system in primary cultures of rat hepatocytes. *Biol. Pharm. Bull.* **22**, 873-875 (1999).
- Kim, S.Y., Lee, E.J., Kim H.P., Lee H.S., and Kim Y.C., LCC, a cerebroside from *Lycium chinense*, protects primary cultured rat hepatocytes exposed to galactosamine. *Phytother. Res.* **14**, 448-451 (2000).
- Kountouras, J., Billing, B.H., and Scheuer, P.J., Prolonged bile duct obstruction: A new experimental model for cirrhosis in the rat. *Br. J. Exp. Pathol.* **65**, 305-311 (1984).
- Krahenbuhl, S., Talos, C., Lauterburg, B.H., and Reichen, J., Reduced antioxidative capacity in liver mitochondria from bile duct ligated rats. *Hepatology* **22**, 607-612 (1995).
- Loguercio, C., Federico, A., Trappoliere, M., Tuccillo, C., de Sio, I., Di Leva, A., Niosi, M., DAuria, M.V., Capasso, R., Del Vecchio Blanco, C., and Real Sud Group, The effect of a silybin-vitamin E-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. *Dig. Dis. Sci.* **52**, 2387-2395 (2007).
- Lopez-de Leon, A. and Rojkind, M.A., Simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. *J. Histochem. Cytochem.* **33**, 737-743 (1985).
- Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J., Protein measurement with the Folin Phenol reagent. *J. Biol. Chem.* **193**, 265-275 (1951).
- Mullen, K.D. and McCullough, A.J., Problems with animal models of chronic liver disease: Suggestions for improvement in standardization. *Hepatology* **9**, 500-503 (1989).
- Muriel, P., Nitric oxide protection of rat liver from lipid peroxidation, collagen accumulation, and liver damage induced by carbon tetrachloride. *Biochem. Pharm.* **56**, 773-779 (1998).
- Muriel, P. and Moreno, M.G., Effects of silymarin and vitamins E and C on liver damage induced by prolonged biliary obstruction in the rat. *Basic Clin. Pharmacol. Toxicol.* **94**, 99-104 (2004).
- Niemela, O., Parkkila, S., Yla-Herttuala, S., Villanueva, J., Ruebner, B., and Halsted, C.H., Sequential acetaldehyde production, lipid peroxidation, and fibrogenesis in a micropig model of alcohol-induced liver disease. *Hepatology* **22**, 1208-1214 (1995).
- Pastor, A., Collado, P.S., Almar, M., and Gonzalez-Gallego, J., Antioxidant enzyme status in biliary obstructed rats: effects of N-acetylcysteine. *J. Hepatol.* **27**, 363-370 (1997).
- Reitman, S. and Frankel, S.A., A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. *Am. J. Clin. Pathol.* **28**, 56-63 (1957).
- Roeb, E., Purucker, E., Gartung, C., Geier, A., Jansen, B., Winograd, R., and Matern, S., Effect of glutathione depletion and hydrophilic bile acid on hepatic acute phase reaction in rats with extrahepatic cholestasis. *Scand. J. Gastroenterol.* **38**, 878-885 (2003).
- Rojkind, M., Rojkind, M.H., and Cerdero-Hernández, J., In vivo collagen synthesis and deposition in fibrotic and regenerating rat livers. *Coll. Relat. Res.* **3**, 335-347 (1983).
- Tietz, N.W., Burtis, C.A., Duncan, P., Ervin, K., Peetclerc, C.J., Rinker, A.D., Shirey, C., and Zygowica, E.R., Reference method for measurement of alkaline phosphatase activity in human serum. Study group on alkaline phosphatase. *Clin. Chem.* **29**, 751-761 (1983).
- Tsukamoto, H., Matsuoka, M., and French, S.W., Experimental models of hepatic fibrosis: a review. *Sem. Liver Dis.* **10**, 56-65 (1990).

Received March 30, 2009

Revised June 24, 2009

Accepted June 24, 2009